The Treatment of Wilson's Disease with Zinc. IV. Efficacy Monitoring Using Urine and Plasma Copper

Abstract

Progress has been made in establishing the efficacy and safety of oral zinc as a maintenance therapy for Wilson''s disease. It is important to develop simple, noninvasive monitoring methods to assure the adequency of zinc therapy in individual patients. In this paper we report the use of 24-hr urine copper and plasma copper measurements to monitor efficacy of zinc maintenance therapy in 30 Wilson''s disease patients. In examples of therapeutic inadequacy such as noncomplicance, these values increase. With continued long-term adequate therapy, they remain stable or decrease. These two simple monitoring tools appear to be very useful in monitoring Wilson''s disease patients receiving zinc therapy.